Novartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patients

NEXT STORY
Chi-Med to Discuss Surufatinib Phase III and U.S. Phase I/Ib Efficacy and Safety Data Presented at the 2019 ESMO Annual Meeting
PREV STORY
G1 Therapeutics Presents First Clinical Data on Oral SERD G1T48 Demonstrating Safety and Tolerability in Patients with Advanced Breast Cancer at ESMO 2019
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Adherium’s Smartinhaler™ Technology Chosen for Major Asthma Initiative

MELBOURNE, Australia, Dec. 09, 2016 (GLOBE NEWSWIRE) -- Adherium Limited (ASX:ADR), a global leader ...

author_avatar
NASDAQ Market News

Cancer Genetics Prices $7 Million Registered Direct Offering

RUTHERFORD, N.J., Dec. 08, 2017 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX), a leader ...

author_avatar
NASDAQ Market News

New England Journal of Medicine Publishes Results of Phase 3 POISE Trial of Ocaliva® (Obeticholic Acid) for the Treatment of PBC

NEW YORK, Aug. 17, 2016 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT), a biopharmaceutical ...

author_avatar
NASDAQ Market News